MetLife and GMC Software Technology to Present Legacy Modernisation at Gartner Symposium
31.10.2012 13:59:25 CET | Business Wire | Press release
Presentation to reveal how global insurance provider transformed customer communications in six weeks
GMC Software Technology, a leading provider of customer communications and output management solutions, today announced its participation at the Gartner Symposium ITxpo, 5-8, November 2012 in Barcelona, Spain. The company is due to present at two speaking sessions alongside global insurance customer, MetLife, as well as hosting a press conference on-site and providing on-stand demonstrations.
Speaking Sessions
Insurance customer, MetLife, will present alongside GMC on legacy modernization in a session titled “Global Financial Services Company Presents Legacy Modernisation in 6 Weeks.” In the session, Nicolas Afonso, Organization and Analysis Manager at MetLife Spain, will reveal how MetLife modernized their legacy customer communication applications in six weeks without impacting their core, mission-critical systems. The session will take place on Wednesday 7, November at 11:15 AM in the Hilton Ballroom.
“IT modernization doesn’t have to mean reinventing core legacy applications, especially when it comes to customer communications,” said Afonso. “With the right approach and tools, enterprises can repurpose and leverage their existing IT investments to deliver more effective communications across multiple channels without taking risks on core systems.”
Prior to his current position, Nicolas Afonso served as Business Administration and Operation Project Manager at MetLife Spain. In addition, he held senior roles at Santander Group Software Development, and Accenture. Afonso’s education includes industrial engineering at Universidad Pontificia de Comillas (ICAI), Madrid and Université Libre de Bruxelles, Brusels as well as education in capital markets and structured finance at the Institute of Advanced Finance.
GMC’s Mike Davies, Regional Vice President of Sales for EMEA North, will also provide a live demonstration of legacy repurposing in a session titled “Legacy Modernisation in 20 Minutes”. The interactive session will show how businesses can take existing, legacy communication applications, mine, extract and repurpose the content for multiple uses, across multiple channels without impacting core, critical systems. Davies’ session takes place on Tuesday 6, November at 12.45 PM on the ITxpo show floor, Theatre 1.
“Businesses are pressured to ensure customer communications conform to the customer’s needs as well as regulatory demands, however many are tied to legacy systems and processes” said Davies. “In the session we aim to demonstrate how businesses can remove the barriers of a legacy environment and achieve faster results on their customer communication objectives.”
Press Conference
GMC Software Technology and MetLife will also hold a press conference for attending press and analysts at Gartner’s ITxpo whereby attendees can see the company’s presentations prior to the public sessions at the event. In addition, representatives from MetLife and GMC will be for available for questions and statements. The press conference takes place on Tuesday 6, November at 4:30-5:30 PM in the Media Theatre.
Stand Demonstrations
GMC will also be exhibiting at the Gartner ITxpo, stand No. A8 in the Applications area of the show floor. The company will be showcasing a range of applications that can help businesses modernize customer communication processes while also leveraging their existing legacy systems to successfully compete in today’s markets.
To schedule a stand demonstration, meeting or attend the press conference, contact beinspired@gmc.net
No. No. No.
GMC Software Technology
GMC Software Technology delivers the most effective solutions in the field of Customer Communications Management (CCM). With unrivalled experience in the industry, GMC has consistently demonstrated the ability to help businesses increase customer engagement across all touch points. The company’s CCM platform, GMC Inspire, enables enterprises to deliver relevant communications, at the right time, through the preferred channel for every customer – driving customer loyalty, acquisition and operational efficiency.
GMC Software Technology serves thousands of clients worldwide across the banking, insurance, retail, business services, telco/utilities and healthcare industry. Having received numerous awards in the field of Customer Communications Management, the company is recognized as an industry leader for innovation.
For more information, please visit www.gmc.net
Facebook: www.facebook.com/gmcnet
Twitter: @gmc_net
Linkedin: www.linkedin.com/company/gmc-software-technology
The GMC logo and GMC Inspire are trademarks of GMC Software Technology
Contact:
North America
Media Ink for GMC Software Technology
Mark
Bonacorso
520-825-0217
markb@mediaink.biz
or
Europe
Naucke
Kommunikation for GMC Software Technology
Christoph Naucke
+49
9151 908890
gmc@naucke.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom